APLT Stock Overview
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Applied Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.35 |
| 52 Week High | US$2.18 |
| 52 Week Low | US$0.50 |
| Beta | 1.89 |
| 1 Month Change | -19.16% |
| 3 Month Change | 39.18% |
| 1 Year Change | 9.76% |
| 3 Year Change | -96.76% |
| 5 Year Change | n/a |
| Change since IPO | -85.64% |
Recent News & Updates
Recent updates
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
May 19
Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Jan 19Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?
Nov 11Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Aug 13Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder
Jun 17Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
May 15Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)
Feb 26How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?
Feb 18Applied Therapeutics to resume galactosemia study for AT-007
Feb 02Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling
Nov 24
Applied Therapeutics EPS misses by $0.21
Nov 12Shareholder Returns
| APLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | 1.3% | 2.1% |
| 1Y | 9.8% | 12.2% | 2.4% |
Return vs Industry: APLT underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: APLT exceeded the US Market which returned -1% over the past year.
Price Volatility
| APLT volatility | |
|---|---|
| APLT Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: APLT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 26 | Shoshana Shendelman | https://www.appliedtherapeutics.com |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.
Applied Therapeutics, Inc. Fundamentals Summary
| APLT fundamental statistics | |
|---|---|
| Market Cap | US$78.10m |
| Earnings (TTM) | -US$69.52m |
| Revenue (TTM) | US$10.66m |
7.3x
P/S Ratio-1.1x
P/E RatioIs APLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLT income statement (TTM) | |
|---|---|
| Revenue | US$10.66m |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.66m |
| Other Expenses | US$80.18m |
| Earnings | -US$69.52m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 100.00% |
| Net Profit Margin | -652.20% |
| Debt/Equity Ratio | 0% |
How did APLT perform over the long term?
See historical performance and comparison